Clinical trials for Breast cancer
204 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Breast cancer
#NCT06380751
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
BRCA 1/2
PALB2
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca
Phase 3
Breast cancer
#NCT05952557
#2023-504031-41-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Chemotherapy
Radiotherapy
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
21 recruiting sites
AstraZeneca
Phase 3
Breast cancer
#NCT04305496
#2019-003629-78
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Hormone therapy
1 recruiting site
AstraZeneca
Phase 3
Breast cancer
#NCT06195709
#2023-506282-66-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
10 recruiting sites
Institut Curie
Phase 3
Breast cancer
#NCT07060807
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
4 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Breast cancer
#NCT04158362
#2024-513005-31-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
1 recruiting site
UNICANCER
Phase 3
Breast cancer
#NCT06016738
#2023-505871-63-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
11 recruiting sites
Olema Pharmaceuticals, Inc.
Phase 3
Breast cancer
#NCT06606730
#2024-515787-31-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Immunotherapy
Chemotherapy
Excluded previous treatments at localized stage
Surgery
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Radiotherapy
Hormone therapy
15 recruiting sites
UNICANCER
Phase 3
Breast cancer
#NCT05232916
#2023-504323-25-01
Required HER2 statuses
HER2 Positive
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
22 recruiting sites
Greenwich LifeSciences, Inc.
Phase 3
Breast cancer
#NCT06312176
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
8 recruiting sites
Merck Sharp & Dohme LLC